Objective: This study evaluated the differences between IDH1-R132H and CD133 expression in different categories of astrocytoma. Material and methods: This study used a cross-sectional design. Sixty-seven paraffin embedded block of Diffuse Astrocytoma (DA), Anaplastic Astrocytoma (AA) and Glioblastoma (GB) were assessed using using the monoclonal antibody IDH1-R132H and Rabbit polyclonal antibody CD133. Results: It was found that there was a significant relationship between the expression of IDH1-R132H and CD133 in DA, AA and GB (p<0.001). Astrocytoma with IDH-mutant molecular status will express more markers of cancer stem cell CD133 than IDH-wildtype. Conclusion: The IDH1-R132H and CD133 can provide predictive value on treatment success, disease prognosis, recurrence and can be considered as target combination therapy with chemotherapy.
Sabunga, O., Kaelan, C., Zainuddin, A., Sungowati, N., Cangara, M. H., & Miskad, U. (2022). Expression of CD133 Cancer Stem Cell Marker in IDH-Mutant and IDH-wildtype (Isocitrate Dehydrogenase) Astrocytoma. Asian Pacific Journal of Cancer Prevention, 23(9), 3051-3059. doi: 10.31557/APJCP.2022.23.9.3051
MLA
Olivia Desty Sabunga; Cahyono Kaelan; Andi Alfian Zainuddin; Ni Ketut Sungowati; Muhammad Husni Cangara; Upik Miskad. "Expression of CD133 Cancer Stem Cell Marker in IDH-Mutant and IDH-wildtype (Isocitrate Dehydrogenase) Astrocytoma". Asian Pacific Journal of Cancer Prevention, 23, 9, 2022, 3051-3059. doi: 10.31557/APJCP.2022.23.9.3051
HARVARD
Sabunga, O., Kaelan, C., Zainuddin, A., Sungowati, N., Cangara, M. H., Miskad, U. (2022). 'Expression of CD133 Cancer Stem Cell Marker in IDH-Mutant and IDH-wildtype (Isocitrate Dehydrogenase) Astrocytoma', Asian Pacific Journal of Cancer Prevention, 23(9), pp. 3051-3059. doi: 10.31557/APJCP.2022.23.9.3051
VANCOUVER
Sabunga, O., Kaelan, C., Zainuddin, A., Sungowati, N., Cangara, M. H., Miskad, U. Expression of CD133 Cancer Stem Cell Marker in IDH-Mutant and IDH-wildtype (Isocitrate Dehydrogenase) Astrocytoma. Asian Pacific Journal of Cancer Prevention, 2022; 23(9): 3051-3059. doi: 10.31557/APJCP.2022.23.9.3051
)